Categories
Change Password!
Reset Password!
Adding OM-85 to standard treatment improves immune markers and reduces the clinical burden of pediatric allergic rhinitis.
Allergic rhinitis (AR) is a common chronic ailment in children that markedly affects daily activities, emotional wellbeing, and overall quality of life. A recent clinical study led by Huajie Yan evaluated whether adding bacterial lysate OM-85 to standard therapy could improve clinical outcomes and immune function in 40 pediatric patients battling AR.
Volunteers (aged 5–14 years) were randomized into two groups:
Before and after treatment, researchers compared the frequency of AR episodes, rhinoconjunctivitis quality of life questionnaire (RQLQ) scores, peripheral blood lymphocyte subsets, and serum immunoglobulin levels. After treatment, both groups experienced a remarkable reduction in the frequency of AR episodes. However, those receiving OM-85 adjunct therapy illustrated broader and more pronounced benefits.
The OM-85 group exhibited remarkable improvements across all RQLQ domains, including daily activities, rhinitis-related behaviors, nasal symptoms, emotional responses, and overall score. The control group illustrated improvement in only selected RQLQ indicators. In the observation group, significant immune modulation was noted after treatment, as depicted in Table 1:
In contrast, no pivotal alteration in immune parameters were detected in the control group. Thus, adjunctive therapy with OM-85 substantially boosts immune regulation, improves clinical symptoms, and leads to broader quality of life benefits. OM-85 may serve as a promising immunomodulatory addition to conventional AR treatment in pediatric populations.
European Archives of Oto-Rhino-Laryngology
The impact of bacterial lysate (OM-85) on clinical and immunological parameters in children with allergic rhinitis
Huajie Yan et al.
Comments (0)